Publication date: May 31, 2025
The COVID-19 pandemic has led to an unexpected rise in patients with increased CMV-IgM antibody titers at our hospital in China, without concurrent evidence of CMV-related organ pathology, prompting an investigation into the relationship between CMV-IgM and COVID-19. We retrospectively analyzed 516 patients tested for CMV-IgG or IgM between January 15 and February 3, 2023. We used Mann-Whitney U and chi-square tests to compare COV2-IgG/IgM profiles between CMV-IgM positive and negative groups. Logistic regression assessed risk factors for increased CMV IgM positivity, adjusting for age, gender, CRP, and CMV IgG. CMV DNA was detected by real-time PCR (detection limit >500 copies/mL), and CMV-IgG/IgM and COV2-IgG/IgM titers were measured by ELISA. Variance analysis compared CRP levels across groups. A notable rise in CMV IgM positivity was observed following the COVID-19 outbreak. The group of patients testing positive for CMV IgM exhibited significantly higher titers of COV2 IgM (0. 83 vs 0. 49, P
| Concepts | Keywords |
|---|---|
| China | Covid-19 |
| Cytomegalovirus | Cytomegalovirus |
| Elisa | Serology |
| February | |
| Organ |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Covid-19 |
| disease | MESH | infection |